Pioneering the application of mAb mixtures

We are pioneering the application of mAb mixtures as a differ­entiated approach to cancer therapy that can overcome some of the limitations of conventional single-target mAbs. A mAb mixture is a combination of two or more systematically selected, well-characterized mAbs developed as a single drug product.

The mAbs in our mixtures may bind different positions on the same target or they may bind different targets. The targets can be on the same or on diverse cell types. Targets are typically cell-surface receptors or ligands. Our mAb mixtures may also be combined with immune checkpoint inhibitors or in combination with other treatment approaches.

mAb mixtures are advantageous compared to traditional mAbs as they provide both specificity and diversity. Diversity is essential in cancer treatment due to the rapid evolution of treatment resistance and evidenced by the rising number of product can­didates combining multiple therapeutics. Due to their diversity, mAb mixtures have the potential to delay or address treatment resistance by synergistic target inhibition or activation, be­ing less sensitive to mutations destroying the antibody binding site, and by addressing heterogeneity of tumors.

5.5 months
Median Overall Survival benefit (12.8 vs. 7.3 months) of Sym004 over investigator choice in biomarker-defined patient population in a Phase 2b trial
Read more
Broad disease focus with multiple shots on goal
Monoclonal antibody (mAb) mixtures against epithelial tumors, mAb or mAb mixtures in immuno-oncology and infectious diseases
Read more
122 patents granted or pending
We actively seek to protect the intellectual property and proprietary information and technology that we believe is important to our business.
Read more

mAb mixtures for RTK inhibition

Our proprietary mAb mixture product candidates consist of pairs of synergistic antibodies designed to bind non-overlapping epitopes on the extra-cellular ligand binding part of a particular RTK. Upon binding the RTK, the antibody pair induces cross-link­ing of the receptor, which in turn triggers internalization and degradation of the receptor-antibody complex. The result is rapid elimination of the oncogenic RTK from the cancer cells, effective receptor inhibition and prevention of tumor growth, as seen in the figure below.

Receptor elimination is an effective mechanism for inhibiting RTK activity and the figure on the right below charts data from a preclinical model comparing Sym004 to the two individual antibodies: 992 (futuximab) and 1024 (modotuximab) constitut­ing the Sym004 mixture as well as the current market-leading anti-EGFR antibody Erbitux® (cetuximab). The Sym004 product induces a pronounced synergistic and durable tumor growth inhibition while the single mAbs only slow down tumor growth.